[1] Khemichian S, Fong TL. Hepatic dysfunction in hyperthyroidism. Gastroenterol Hepatol (N Y),2011,7(5): 337-339.
[2] De Campos Mazo DF, De Vasconcelos GB, Pereira MA, et al. Clinical spectrum and therapeutic approach to hepatocellular injury in patients with hyperthyroidism. Clin Exp Gastroenterol,2013,6: 9-17.
[3] Boelaert K, Newby PR, Simmonds MJ, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med,2010,123(2): 183,e1-183,e9.
[4] Ashkar FS, Miller R, Smoak WM 3rd, et al. Liver disease in hyperthyroidism. South Med J,1971,64(4): 462-465.
[5] Lin TY, Shekar AO, Li N, et al. Incidence of abnormal liver biochemical tests in hyperthyroidism. Clin Endocrinol (Oxf),2017,86(5): 755-759.
[6] He K, Hu Y, Xu XH, et al. Hepatic dysfunction related to thyrotropin receptor antibody in patients with Graves' disease. Exp Clin Endocrinol Diabetes,2014,122(6): 368-372.
[7] Lyu T, Li M, Zeng N, et al. Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population. J Gastroenterol Hepatol,2019,34(10): 1676-1684.
[8] Komori A. Recent updates on the management of autoimmune hepatitis. Clin Mol Hepatol,2021,27(1): 58-69.
[9] Yorke E. Hyperthyroidism and liver dysfunction: A review of a common comorbidity. Clin Med Insights Endocrinol Diabetes,2022,15: 11795514221074672.
[10] Rana S, Ahmed Z, Salgia R, et al. Successful management of patients with co-existent Graves' disease and autoimmune hepatitis. Cureus,2019,11(5): e4647.
[11] Patel AM, Stanback C, Vellanki P. Clinical case report: Dissociation of clinical course of coexisting autoimmune hepatitis and Graves disease. AACE Clin Case Rep,2020,7(1): 36-39.
[12] Salvi M, Vannucchi G, Sbrozzi F, et al. Onset of autoimmune hepatitis during intravenous steroid therapy for thyroid-associated ophthalmopathy in a patient with Hashimoto's thyroiditis: case report. Thyroid,2004,14(8): 631-634.
[13] Hartl J, Miquel R, Zachou K, et al. Features and outcome of AIH patients without elevation of IgG. JHEP Rep,2020,2(3): 100094.
[14] Lleo A, Wang GQ, Gershwin ME, et al. Primary biliary cholangitis. Lancet,2020,396(10266): 1915-1926.
[15] Floreani A, Mangini C, Reig A, et al. Thyroid dysfunction in primary biliary cholangitis: A comparative study at two European centers. Am J Gastroenterol,2017,112(1): 114-119.
[16] Floreani A, Franceschet I, Cazzagon N, et al. Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clin Rev Allergy Immunol,2015,48(2-3): 192-197.
[17] Shetty S, Rajasekaran S, Venkatakrishnan L. Grave's disease and primary biliary cirrhosis-An unusual and challenging association. J Clin Exp Hepatol,2014,4(1): 66-67.
[18] Liu Y, Han K, Liu C, et al. Clinical characteristics and prognosis of concomitant primary biliary cholangitis and autoimmune diseases: A retrospective study. Can J Gastroenterol Hepatol,2021,2021: 5557814.
[19] Suzuki Y, Ishida K, Takahashi H, et al. Primary biliary cirrhosis associated with Graves' disease in a male patient. Clin J Gastroenterol,2016,9(2): 99-103.
[20] Koyamada R, Higuchi T, Kitada A, et al. Association of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome with immune thrombocytopenia and Graves' disease. Intern Med,2015,54(16): 2013-2016.
[21] Lowe D, John S. Autoimmune hepatitis: Appraisal of current treatment guidelines. World J Hepatol,2018,10(12): 911-923.
[22] Wang R, Tan J, Zhang G, et al. Risk factors of hepatic dysfunction in patients with Graves' hyperthyroidism and the efficacy of 131iodine treatment. Medicine (Baltimore),2017,96(5): e6035.
[23] Yang J, Li LF, Xu Q, et al. Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China. Thyroid,2015,25(3): 278-283.
[24] Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid,2016,26(10): 1343-1421.
[25] Zachou K, Gatselis N, Papadamou G, et al. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol,2011,55(3): 636-646.
[26] Tanaka A. Current understanding of primary biliary cholangitis. Clin Mol Hepatol,2021,27(1): 1-21. |
